GR852858B - - Google Patents

Info

Publication number
GR852858B
GR852858B GR852858A GR850102858A GR852858B GR 852858 B GR852858 B GR 852858B GR 852858 A GR852858 A GR 852858A GR 850102858 A GR850102858 A GR 850102858A GR 852858 B GR852858 B GR 852858B
Authority
GR
Greece
Prior art keywords
difluoronucleosides
mammals
useful
treating neoplasms
neoplasms
Prior art date
Application number
GR852858A
Other languages
English (en)
Inventor
Gerald Burr Grindey
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR852858(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GR852858B publication Critical patent/GR852858B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
GR852858A 1984-12-04 1985-11-27 GR852858B (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67778384A 1984-12-04 1984-12-04
US78641985A 1985-10-10 1985-10-10

Publications (1)

Publication Number Publication Date
GR852858B true GR852858B (el) 1986-03-28

Family

ID=27101898

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852858A GR852858B (el) 1984-12-04 1985-11-27

Country Status (21)

Country Link
US (1) US5464826A (el)
EP (1) EP0184365B1 (el)
JP (1) JPH0637394B2 (el)
KR (2) KR890003439B1 (el)
CN (1) CN1020194C (el)
AT (1) ATE92499T1 (el)
AU (1) AU581269B2 (el)
CA (1) CA1264738A (el)
CY (1) CY1806A (el)
DE (1) DE3587500T2 (el)
DK (1) DK162965C (el)
EG (1) EG17765A (el)
ES (1) ES8801546A1 (el)
GR (1) GR852858B (el)
HK (1) HK113693A (el)
HU (1) HU194273B (el)
IE (1) IE60328B1 (el)
IL (1) IL77133A (el)
NZ (1) NZ214364A (el)
PH (1) PH23172A (el)
PT (1) PT81559B (el)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) * 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0630905B1 (en) * 1987-08-28 1999-05-06 Eli Lilly And Company Process for selectively isolating beta-2'-deoxy-2',2'-difluorocytidine or its salts
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
DE69812934T2 (de) * 1997-01-24 2004-01-29 Conpharma As Oslo Gemcitabin-derivate
AU6473098A (en) * 1997-03-24 1998-10-20 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0019124D0 (en) * 2000-08-03 2000-09-27 Pfizer Novel process
ATE355275T1 (de) * 2000-10-20 2006-03-15 Eisai R&D Man Co Ltd Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en) * 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
BR0306861A (pt) 2002-01-14 2004-11-03 Novartis Ag Combinações que compreendem epotilonas e antimetabólitos
WO2003059339A1 (en) * 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US20080026044A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
US20080026045A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising a Gemcitabine and a Liposomal Platium Complex
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
WO2005044788A1 (ja) * 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
EP1711188B1 (en) * 2004-02-06 2012-06-06 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
JP2007533742A (ja) * 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー 癌治療のための薬剤併用療法
AU2005283422C1 (en) * 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US20060089329A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
EP1819718A1 (en) * 2004-12-08 2007-08-22 Sicor Inc. Difluoronucleosides and process for preparation thereof
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
TW200637870A (en) 2005-01-31 2006-11-01 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound and salt thereof
GEP20094822B (en) * 2005-03-04 2009-11-10 Dabur Pharma Ltd Intermediate and process for preparing of beta- anomer enriched 21-deoxy, 21, 21-difluoro-d-ribofuranosyl nucleosides
TWI368621B (en) 2005-05-02 2012-07-21 Leyoung Biotech Co Ltd Stereoselective synthesis of β-nucleosides
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
KR20080047402A (ko) * 2005-08-26 2008-05-28 안티소마 피엘씨 Ｄｍｘａａ를 포함하는 암 치료용 조합물
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
WO2008010571A1 (fr) 2006-07-21 2008-01-24 Taiho Pharmaceutical Co., Ltd. Composé nucléosidique de 2'cyanopyrimidine
ATE525386T1 (de) 2006-07-24 2011-10-15 Taiho Pharmaceutical Co Ltd 3'-ethynylcytidinderivat
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US7714012B2 (en) * 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008088088A1 (ja) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. 膵癌治療用組成物
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
EP2217247A4 (en) 2007-11-06 2011-12-28 Pharmaessentia Corp NEW SYNTHESIS OF BETA NUCLEOSIDES
CA2705092A1 (en) * 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
AU2009203941B2 (en) 2008-01-11 2015-03-12 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids and methods of use in the treatment of disease
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
TWI442925B (zh) 2008-04-18 2014-07-01 Reata Pharmaceuticals Inc 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
SI2276493T1 (sl) 2008-04-18 2019-04-30 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: derivati oleanolne kisline z amino in drugimi modifikacijami pri C-17
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
EP2416780B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8324180B2 (en) * 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
RS56759B1 (sr) 2011-04-01 2018-04-30 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CA2986512C (en) 2012-04-04 2022-05-17 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
MX2016015280A (es) 2014-06-26 2017-03-03 Hoffmann La Roche Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
FI3263106T3 (fi) 2015-02-25 2024-01-03 Eisai R&D Man Co Ltd Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN106317147B (zh) * 2015-07-06 2018-11-27 扬州硒瑞恩生物医药科技有限公司 核苷类化合物及其制备方法
US20200306254A1 (en) 2016-06-29 2020-10-01 Eli Lilly And Company Combination of erk1/2 inhibitor compound with gemcitabine or with gemcitabine and nab-paclitaxel for use in treatment of pancreatic cancer
WO2018094406A1 (en) 2016-11-21 2018-05-24 Bexion Pharmaceuticals, Inc. A combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
AU2018314227A1 (en) 2017-08-07 2020-02-06 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
AU2018334434A1 (en) 2017-09-18 2020-04-02 The Regents Of The University Of California Claudin6 antibodies and methods of treating cancer
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019152955A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Small molecule drug conjugates of gemcitabine monophosphate
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020001475A1 (en) 2018-06-29 2020-01-02 Shanghai Changchengyiyaokeji Company Limited Phosphorus-containing prodrugs of gemcitabine
WO2020058405A1 (en) 2018-09-20 2020-03-26 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US20220087975A1 (en) 2019-01-11 2022-03-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
CN114174340A (zh) 2019-03-20 2022-03-11 加利福尼亚大学董事会 密封蛋白-6抗体和药物缀合物
BR112021021663A2 (pt) 2019-04-30 2022-05-17 Inst De Medicina Molecular Joao Lobo Antunes Inibidores da via rank em combinação com inibidores de cdk
EP3980541A1 (en) 2019-06-04 2022-04-13 Apterna Limited Aptamers against transferrin receptor (tfr)
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
CN110684062B (zh) * 2019-10-18 2022-12-13 大连大学 一种治疗非小细胞肺癌的药物及其制备方法
GB202019692D0 (en) 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (el) *
US3705147A (en) * 1969-08-22 1972-12-05 Univ Utah 3-deazapyrimidine nucleosides and method of preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
JPS5136467A (en) * 1974-09-20 1976-03-27 Tanabe Seiyaku Co 11 beetaa dd2** harogeno 2** deokishiribofuranoshirurashirujudotai no seiho
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類

Also Published As

Publication number Publication date
ATE92499T1 (de) 1993-08-15
IE853038L (en) 1986-06-04
KR890003426B1 (ko) 1989-09-20
HU194273B (en) 1988-01-28
DK549685A (da) 1986-06-05
PT81559B (pt) 1988-03-03
CA1264738A (en) 1990-01-23
KR860004920A (ko) 1986-07-16
EP0184365A2 (en) 1986-06-11
PH23172A (en) 1989-05-19
EG17765A (en) 1990-08-30
EP0184365B1 (en) 1993-08-04
EP0184365A3 (en) 1988-01-27
KR890003439B1 (ko) 1989-09-21
DK549685D0 (da) 1985-11-28
JPH0637394B2 (ja) 1994-05-18
CN85109409A (zh) 1986-08-27
HK113693A (en) 1993-10-29
AU5055585A (en) 1986-06-12
DE3587500D1 (de) 1993-09-09
US5464826A (en) 1995-11-07
DE3587500T2 (de) 1993-12-16
HUT39188A (en) 1986-08-28
IL77133A (en) 1991-01-31
CN1020194C (zh) 1993-03-31
ES549547A0 (es) 1987-08-01
ES8801546A1 (es) 1987-08-01
IE60328B1 (en) 1994-06-29
JPS61148193A (ja) 1986-07-05
DK162965B (da) 1992-01-06
DK162965C (da) 1992-06-01
AU581269B2 (en) 1989-02-16
CY1806A (en) 1995-09-08
NZ214364A (en) 1988-11-29
PT81559A (en) 1985-12-01

Similar Documents

Publication Publication Date Title
GR852858B (el)
EP0189680A3 (en) Stabilizing power source apparatus
GB8518738D0 (en) Power source
GB2162365B (en) Ion source
JPS57111963A (en) Dc power source
EP0154824A3 (en) Ion source
GB8414113D0 (en) Treating textiles
SG87090G (en) Cascode current source arrangement
GB8525981D0 (en) Treating fabric for shrinkage
GB8515478D0 (en) Light source
GB2156036B (en) Tensioning pulley
GB8519615D0 (en) Treating leather
GB8422190D0 (en) Belt guides
JPS56159931A (en) Dc power source
JPS56160798A (en) Dc power source
GB8419039D0 (en) Ion source
GB2083954B (en) Improved power source
JPS5731340A (en) Dc power source
GB8306487D0 (en) Pulley assemblies
GB8412753D0 (en) Pulleys
PL254559A1 (en) Planing apparatus
PL248993A1 (en) Turning over machine for plate-like members
YU113684A (en) Numerical reference dc tension source
BG46901A3 (en) Biocidic means
SU1156875A1 (en) Power supply source